Scheinberg A, O'Flaherty S, Chaseling R, Dexter M
Department of Rehabilitation, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
J Paediatr Child Health. 2001 Jun;37(3):283-8. doi: 10.1046/j.1440-1754.2001.00676.x.
To determine whether continuous intrathecal baclofen infusion (CIBI) would decrease spasticity and improve function in children with spastic cerebral palsy.
Prospective study with measurement of changes from baseline assessed at regular intervals for 6 months following the intervention.
Two subjects aged 8 and 9 years with cerebral palsy. Inclusion criteria included severe spasticity and age greater than 4 years. STUDY CENTRE: Department of Rehabilitation, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
Both subjects had clinically significant reductions in lower limb spasticity from a single intrathecal dose of baclofen (screening procedure), and had intrathecal pumps implanted. An intensive physical therapy programme was provided for both subjects in the 1-3-month period after commencing CIBI, in order to maximize functional gains. Modified Ashworth Scale scores remained reduced during the 6-month study period. There was a clinically significant increase in upper limb function for Subject 1. Gross Motor Function Measure scores decreased from 22% to 19% for Subject 1, and increased from 6% to 10% for Subject 2 over the study period. Paediatric Evaluation of Disability Inventory scores for Subject 1 showed a reduction in the level of caregiver assistance required, while Subject 2 showed significant improvement in the functional mobility domain. The major changes noted in the parent questionnaires were reduction in tone, increased range of motion and reduced time taken helping with activities of daily living such as toilet and dressing. No significant side-effect was seen after the screening procedure or after continuous intrathecal infusion. Both subjects' parents felt their child was improved following the intervention.
Children with spastic cerebral palsy can have their spasticity effectively reduced with CIBI. In this study of two children, the clinical improvements were encouraging, and it is proposed that CIBI may be of benefit to those patients whose level of spasticity severely interferes with function. Further studies using multidimensional assessment approaches, with larger numbers of children, are warranted.
确定鞘内持续注入巴氯芬(CIBI)是否会降低痉挛性脑瘫患儿的痉挛程度并改善其功能。
前瞻性研究,在干预后6个月内定期测量相对于基线的变化。
两名8岁和9岁的脑瘫患儿。纳入标准包括严重痉挛和年龄大于4岁。研究中心:澳大利亚新南威尔士州韦斯特米德韦斯特米德儿童医院康复科。
两名受试者在鞘内单次注射巴氯芬(筛查程序)后下肢痉挛程度均有临床显著降低,并植入了鞘内泵。在开始CIBI后的1 - 3个月期间,为两名受试者提供了强化物理治疗方案,以最大程度地提高功能收益。在6个月的研究期间,改良Ashworth量表评分持续降低。受试者1的上肢功能有临床显著改善。在研究期间,受试者1的粗大运动功能测量评分从22%降至19%,受试者2从6%升至10%。受试者1的儿童残疾评估量表评分显示照顾者所需协助水平降低,而受试者2在功能移动领域有显著改善。家长问卷中指出的主要变化是肌张力降低、活动范围增加以及帮助进行如如厕和穿衣等日常生活活动所需时间减少。在筛查程序或鞘内持续注入后未观察到显著副作用。两名受试者的家长都认为干预后孩子有所改善。
痉挛性脑瘫患儿可通过CIBI有效降低痉挛程度。在这项对两名儿童的研究中,临床改善令人鼓舞,建议CIBI可能对痉挛程度严重影响功能的患者有益。有必要使用多维评估方法对更多儿童进行进一步研究。